Rallybio Corporation
RLYB
NASDAQ·Healthcare·Biotechnology·Mkt cap $89.8M
$16.93
▲ +0.30%
P/E
2.73
Mkt Cap
$89.8M
52-Wk Range
$3.67–$17.57
52-Week Range
$3.67 - $17.57
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 256.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -0.8).
Growth
Profitability at risk
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+6.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RLYB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$1.09 vs -$1.28 consensus (+14.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+14.8%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$212.0K
$0
Margins · last 2Q
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How RLYB stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.